Y-ST04-PRIT

Y-ST04-PRIT is a preclinical-stage radiopharmaceutical candidate being developed by Y-mAbs Therapeutics for the treatment of solid tumors. It utilizes the company's proprietary Self-Assembly DisAssembly (SADA) pre-targeted radioimmunotherapy (PRIT) platform. This technology involves a two-step dosing regimen: first, a bispecific SADA protein is administered, which binds to a specific tumor antigen and self-assembles into a stable tetramer; once the unbound protein has cleared from the circulation, a small-molecule radioactive payload is administered. This payload specifically binds to the pre-localized SADA protein at the tumor site, delivering a concentrated dose of radiation while minimizing exposure to healthy tissues like the bone marrow. The specific molecular target for the Y-ST04-PRIT program is currently undisclosed.